CONSIDERATIONS TO KNOW ABOUT AGO TUMOR

The corresponding relative hazard reduction is very depending on the tumor biology than to the nodal status and extent of condition [sixty two].In case of pT2 pN0 a taxane based mostly polychemotherapy in addition trastuzumab monotherapy is suggested which could be followed in the event of a HR+ tumor by neratinib monotherapy for as many as one yr.